<div id="readability-page-1"><p>Chardan Capital analyst Geulah Livshits maintained a Buy rating on Metagenomi, Inc. today and set a price target of $7.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Lexeo Therapeutics, Inc., and Intellia Therapeutics. According to TipRanks, Livshits has an average return of <span>22.2%</span> and a 41.55% success rate on recommended stocks. </p> <p>In addition to Chardan Capital, Metagenomi, Inc. also received a Buy from TD Cowen’s Joseph Thome in a report issued yesterday. However, on November 8, TR | OpenAI – 4o reiterated a Hold rating on Metagenomi, Inc. (NASDAQ: MGX).</p></div>

<p>Chardan Capital analyst Geulah Livshits has maintained a Buy rating on Metagenomi, Inc. (MGX) with a price target of $7.00. Livshits, who focuses on the Healthcare sector, has an average return of 22.2% and a 41.55% success rate on recommended stocks. Additionally, TD Cowen's Joseph Thome also issued a Buy rating for Metagenomi, while TR | OpenAI reiterated a Hold rating on November 8.</p>

Chardan Capital Keeps Their Buy Rating on Metagenomi, Inc. (MGX)